Pulse Biosciences announced on January 21, 2025, the presentation of late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study at the 30th Annual AF Symposium 2025 meeting. The study demonstrated 100% acute successful electrical isolation in treated pulmonary veins and left atrial posterior walls.
Crucially, three-month remapping data showed durable pulmonary vein isolation in 94.2% of treated veins and left atrial posterior wall isolation in 95.5% of treated patients within a 22-patient cohort. These results indicate strong efficacy and durability for the company's novel ablation technology.
The study also highlighted procedural efficiency, with an average left atrial dwell time of 26.2 minutes and fluoroscopy time of 6.5 minutes. This positive data supports the potential of the 360° Cardiac Catheter System to advance the treatment of atrial fibrillation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.